ESMO 2022: Breast and ovarian trial analysis

Bookmark and Share
Published: 14 Sep 2022
Views: 278
Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal gives ecancer his analysis of the key breast and ovarian studies from ESMO 2022.

He covers the following studies:

Overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
Final overall survival results from the phase III PAOLA- 1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer (AOC)
ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
Phase III ATALANTE/ov29 trial: Atezolizumab versus placebo with platinum-based chemotherapy plus bevacizumab in patients with platinum-sensitive relapse of epithelial ovarian cancer
MONARCH 3: Interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer.
Dalpiciclib plus fulvestrant in HR+/HER2L advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
Overall survival results from the phase III TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in patients with HRD/HER2- metastatic breast cancer
Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial
Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)